EMPIRI's E-slice 3D tumor culture platform for real-time evaluation of therapeutic candidates can now be accessed through our store-front at Scienist.Com for expedited study quoting and contracting. https://app.scientist.com/providers/empiri-inc E-slice enables efficacy, target validation, and MOA studies, including chemo, targeted, immune, virotherapy, cell-based and combinations while maintaining the native TME cell-cell and cell-matrix interactions unique to each patient

We are excited and grateful to announce being awarded "Most Promising Company" following the pitch competition at the 2022 Texas Life Science Forum! #lifescience #precisionmedicine #oncology #biotech